USCB:NASDAQUSCB Financial Holdings, Inc. Analysis
Data as of 2026-07-01 - not real-time
$20.46
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
USCB is trading at $20.46, well below its discounted cash flow fair value of roughly $40, indicating a substantial upside potential. Technicals remain bullish with the 20‑day SMA at $19.37, price above both the 50‑day ($18.89) and 200‑day ($18.55) averages, a bullish MACD histogram, and a rising volume trend, while the RSI of 68 suggests momentum is still strong but approaching overbought levels. The stock also offers a solid 2.45% dividend yield with a modest payout ratio of 29%, supporting income‑focused investors.
Recent corporate governance news – the appointment of Sergio E. Garrido as Senior Vice President and Chief Credit Officer – underscores management depth and continuity, which may further bolster credit quality and earnings stability. Combined with a low beta of ~0.5 and a moderate 30‑day volatility of ~22%, USCB presents a compelling blend of value upside and defensive characteristics.
Recent corporate governance news – the appointment of Sergio E. Garrido as Senior Vice President and Chief Credit Officer – underscores management depth and continuity, which may further bolster credit quality and earnings stability. Combined with a low beta of ~0.5 and a moderate 30‑day volatility of ~22%, USCB presents a compelling blend of value upside and defensive characteristics.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance level of $20.93
- RSI approaching overbought territory
- Strong dividend yield supporting total return
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation gap to DCF fair value
- Consistent earnings growth and operating margins
- Management continuity with new Chief Credit Officer
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Sustained dividend income and low payout ratio
- Regional banking sector exposure to economic cycles
- Undervalued valuation providing margin of safety
Key Metrics & Analysis
Financial Health
Revenue Growth14.70%
Profit Margin30.48%
P/E Ratio13.9
ROE12.40%
ROA1.01%
P/B Ratio1.7
Op. Cash Flow$43.5M
Industry P/E16.9
Technical Analysis
TrendBullish
RSI67.7
Support$17.99
Resistance$20.93
MA 20$19.37
MA 50$18.89
MA 200$18.55
MACDBullish
VolumeIncreasing
Fear & Greed Index91.14
Valuation
Fair Value$40.10
Target Price$21.70
Upside/Downside6.06%
GradeUndervalued
TypeBlend
Dividend Yield2.45%
Risk Assessment
Beta0.61
Volatility21.99%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.